2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance

Shih Chieh Chien, Po-Sheng Chen, Yi Hsiang Huang, Sung Chun Tang, Yi-Heng Li, Hung I. Yeh

研究成果: Review article

1 引文 (Scopus)

摘要

Statin reduces low-density lipoprotein cholesterol and improves clinical outcomes in high risk patients. In general, statin is a safe and well-tolerated medication. However, varieties of adverse effects are reported in some patients and may interfere long-term drug compliance. Statin-associated muscle events and liver function change account for most of these adverse effects. Patients are regarded as statin intolerance if they need to discontinue statin therapy due to these adverse effects. To date, there is no universal standard definition of statin intolerance. But a pragmatic definition of statin intolerance is essential and helpful for clinicians in daily practice. In this article, after expert consensus meetings and literature review, criteria were recommended to identify patients with statin intolerance in Taiwan. The purpose of this statement is to help health care professionals in Taiwan to diagnose and manage individuals who develop muscular and hepatic side effects after statin therapy.

原文English
頁(從 - 到)1385-1392
頁數8
期刊Journal of the Formosan Medical Association
118
發行號10
DOIs
出版狀態Published - 2019 十月 1

指紋

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Taiwan
Atherosclerosis
Lipids
Liver
LDL Cholesterol
Delivery of Health Care
Muscles

All Science Journal Classification (ASJC) codes

  • Medicine(all)

引用此文

Chien, Shih Chieh ; Chen, Po-Sheng ; Huang, Yi Hsiang ; Tang, Sung Chun ; Li, Yi-Heng ; Yeh, Hung I. / 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance. 於: Journal of the Formosan Medical Association. 2019 ; 卷 118, 編號 10. 頁 1385-1392.
@article{a7aeade25b5d461c84d0bbca68eb9017,
title = "2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance",
abstract = "Statin reduces low-density lipoprotein cholesterol and improves clinical outcomes in high risk patients. In general, statin is a safe and well-tolerated medication. However, varieties of adverse effects are reported in some patients and may interfere long-term drug compliance. Statin-associated muscle events and liver function change account for most of these adverse effects. Patients are regarded as statin intolerance if they need to discontinue statin therapy due to these adverse effects. To date, there is no universal standard definition of statin intolerance. But a pragmatic definition of statin intolerance is essential and helpful for clinicians in daily practice. In this article, after expert consensus meetings and literature review, criteria were recommended to identify patients with statin intolerance in Taiwan. The purpose of this statement is to help health care professionals in Taiwan to diagnose and manage individuals who develop muscular and hepatic side effects after statin therapy.",
author = "Chien, {Shih Chieh} and Po-Sheng Chen and Huang, {Yi Hsiang} and Tang, {Sung Chun} and Yi-Heng Li and Yeh, {Hung I.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.jfma.2018.11.017",
language = "English",
volume = "118",
pages = "1385--1392",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Excerpta Medica Asia Ltd.",
number = "10",

}

2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance. / Chien, Shih Chieh; Chen, Po-Sheng; Huang, Yi Hsiang; Tang, Sung Chun; Li, Yi-Heng; Yeh, Hung I.

於: Journal of the Formosan Medical Association, 卷 118, 編號 10, 01.10.2019, p. 1385-1392.

研究成果: Review article

TY - JOUR

T1 - 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance

AU - Chien, Shih Chieh

AU - Chen, Po-Sheng

AU - Huang, Yi Hsiang

AU - Tang, Sung Chun

AU - Li, Yi-Heng

AU - Yeh, Hung I.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Statin reduces low-density lipoprotein cholesterol and improves clinical outcomes in high risk patients. In general, statin is a safe and well-tolerated medication. However, varieties of adverse effects are reported in some patients and may interfere long-term drug compliance. Statin-associated muscle events and liver function change account for most of these adverse effects. Patients are regarded as statin intolerance if they need to discontinue statin therapy due to these adverse effects. To date, there is no universal standard definition of statin intolerance. But a pragmatic definition of statin intolerance is essential and helpful for clinicians in daily practice. In this article, after expert consensus meetings and literature review, criteria were recommended to identify patients with statin intolerance in Taiwan. The purpose of this statement is to help health care professionals in Taiwan to diagnose and manage individuals who develop muscular and hepatic side effects after statin therapy.

AB - Statin reduces low-density lipoprotein cholesterol and improves clinical outcomes in high risk patients. In general, statin is a safe and well-tolerated medication. However, varieties of adverse effects are reported in some patients and may interfere long-term drug compliance. Statin-associated muscle events and liver function change account for most of these adverse effects. Patients are regarded as statin intolerance if they need to discontinue statin therapy due to these adverse effects. To date, there is no universal standard definition of statin intolerance. But a pragmatic definition of statin intolerance is essential and helpful for clinicians in daily practice. In this article, after expert consensus meetings and literature review, criteria were recommended to identify patients with statin intolerance in Taiwan. The purpose of this statement is to help health care professionals in Taiwan to diagnose and manage individuals who develop muscular and hepatic side effects after statin therapy.

UR - http://www.scopus.com/inward/record.url?scp=85058695124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058695124&partnerID=8YFLogxK

U2 - 10.1016/j.jfma.2018.11.017

DO - 10.1016/j.jfma.2018.11.017

M3 - Review article

AN - SCOPUS:85058695124

VL - 118

SP - 1385

EP - 1392

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 10

ER -